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My final project was carried out for Cancer Gene Therapy Group, University of Helsinki, 
Finland; to enable further research projects with vvD-GFP.The main aim of my work was to 
carry out and describe a large scale vaccinia virus (VV) preparation and to amplify the titer 
of vvD-GFP. Due to the problematic nature of fetal bovine serum (FBS) in cell cultures, 
one aim was to investigate whether culturing in serum-free medium affected the cell viabil-
ity of A549 cells and to find out whether it was possible to amplify vvD-GFP in serum-free 
culture. In order to get reliable virus titer results, the aim was to compare titers between 
two titering methods; plaque and TCID50 assay. 
 
I carried out two large scale VV preparations, one in culture with 2% FBS and one in se-
rum-free culture. The existence of transgene, GFP, was confirmed with a fluorescent mi-
croscope. In addition, I incubated A549 cells in serum-free medium and in medium with 
10% FBS and measured the cell viability with tetrazolium (MTS) based assay on three 
consecutive days. Then, I compared the results and demonstrated them in diagram. Fur-
thermore, I quantified the virus titer from both virus preparations using two different titering 
methods, compared the titers with both assays and evaluated the reliability of these re-
sults.  
 
It was possible to amplify vvD-GFP in serum-free culture without remarkable loss of virus 
titer. The virus titer in serum-free culture was 12% lower than in culture with 2% FBS. The 
cell culture of A549 cells in serum-free medium was possible at least for a short time but it 
was less efficient. Difference in virus titers between the two different titering methods oc-
curred. 
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Tein opinnäytetyöni Helsingin Yliopiston Cancer Gene Therapy Group-tutkimusryhmälle. 
Työni päätavoitteena oli tuottaa tiettyä vaccinia-virusta (vvD-GFP) tulevia tutkimuksia var-
ten sekä kuvata tuotantoprosessin eri työvaiheet. Soluviljelyssä käytettävän seerumin 
(FBS) ongelmallisuuden vuoksi, tavoitteenani oli myös selvittää vaikuttaako seerumiton 
kasvatusliuos A549-solujen elinkykyyn sekä selvittää, onko vaccinia-virusta mahdollista 
tuottaa ilman seerumin käyttöä. Luotettavan virustitterin saamiseksi, tavoitteenani oli lisäk-
si tehdä virustitterin määritys kahdella eri menetelmällä, plakki- ja TCID50-menetelmällä, 
sekä verrata niistä saatuja tuloksia keskenään.  
 
Tein vaccinia-viruksesta kaksi virusvalmistetta. Toisen valmisteen tuotin seerumittomassa 
soluviljelmässä ja toisen 2 % seerumia sisältävässä soluviljelmässä. Viruksen GFP-
transgeenin osoitin fluoresenssimikroskoopin avulla. Kasvatin A549-soluja sekä seerumit-
tomassa että 10 % seerumia sisältävässä kasvatusliuoksessa ja mittasin solujen elinkykyä 
kolmena peräkkäisenä päivänä MTS-analyysillä. Vertasin saamiani tuloksia keskenään ja 
havainnollistin tuloksia taulukon avulla. Määritin virustitterit molemmista valmisteista kah-
della eri titteröinti menetelmällä ja vertasin tuloksia keskenään sekä arvioin menetelmien 
luotettavuutta. 
 
Tulosten mukaan vaccinia-virusta (vvD-GFP) oli mahdollista tuottaa A549-soluissa seeru-
mittomassa viljelmässä ilman merkittävää virustitterin laskua. Seerumittomassa soluviljel-
mässä tuotetun virusvalmisteen titteri oli noin 12 % pienempi kuin tavallisessa, seerumia 
sisältävässä, viljelmässä. A549-solujen viljely seerumittomassa kasvatusliuoksessa oli 
mahdollista ainakin lyhyen aikaa, mutta solut eivät kasvaneet siinä yhtä tehokkaasti. Virus-
tittereissä kahden eri menetelmän välillä esiintyi eroja. 
 
Avainsanat vaccinia virus, viruksen valmistus, seerumiton soluviljely, plakki-
määritys, TCID50 
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1 Introduction 
 
Cancer Gene Therapy Group (CGTG) is a research group of University of Helsinki, 
Finland, led by research professor Akseli Hemminki (MD, PhD). The mission of this 
group is to improve cancer treatments by exploring and developing novel, more effi-
cient cancer treatments.  The approaches to this development are the use of gene 
therapy and oncolytic viruses. Under special interest are such malignant cancers which 
currently are lacking effective treatments.  
 
Approximately, every second man and every third woman is affected by cancer at 
some point in their life. Conventional cancer therapies, like surgery, chemo- and radio-
therapy, are not always effective enough alone to defeat cancer, and often they have 
severe side effects. New therapy options are desperately needed for treating cancer, 
and hence, the design of efficient cancer treatments is one of the major challenges of 
medical science. A combination of traditional and novel cancer treatment may improve 
the patient’s prognosis, or even cure the patient if the cancer is detected early enough. 
Gene therapy and oncolytic viruses hold great promise for the development of novel 
cancer therapies. Oncolytic vaccinia virus (VV) has emerged as a promising candidate 
for gene therapy agent. Different generated recombinant vaccinia viruses have shown 
convincing preclinical results; however, this new type of therapy also raises some safe-
ty concerns. Hence, more research work is needed and the antitumor efficacy and 
safety need to be demonstrated by randomized clinical trials. (Cross – Burmester 2006: 
218-219; Guse – Cerullo – Hemminki 2011: 603; Rajecki – Joensuu – Hemminki 2008: 
3085, 3091.)   
 
This final project was carried out in co-operation with Cancer Gene Therapy Group. 
The practical execution of this project was carried out during a six weeks practical train-
ing period, under the guidance of supervisor Kilian Guse, laboratory technician Eerika 
Karli and the assistance of other members of the group. The subject of this final project 
came from supervisor Kilian Guse. The subject developed according to the needs of 
the research group at that time and obtained the final form during the execution period. 
 
The aim of the project was to carry out a large scale vaccinia virus preparation to pro-
duce large amounts of a recombinant VV, named as vvD-GFP, which would then be 
used by the research group in experiments. To be able to reduce the use of fetal bo-
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vine serum (FBS), I carried out another VV preparation in serum-free cell culture be-
side the actual preparation and compared the results with each other. In addition, I tried 
to find out how serum-free culture affects the cell growth and viability of the VV produc-
er cell line A549. I performed a cell viability assay using a tetrazolium (MTS) based 
CellTiter 96® AQueous One Solution Cell Proliferation Assay. The final aim was to quan-
tify the virus titers from both VV preparations using two tittering methods; plaque and 
TCID50 assay, and compare the results. Finally, I tried to evaluate the reliability of the 
methods.     
 
2 Background  
 
2.1 Gene Therapy in General 
 
Gene therapy can be defined as a transfer of genetic material into patient´s somatic 
cells to treat or prevent disease. Genes can be used to treat both acquired and inherit-
ed diseases, by replacing the defective gene with the functioning version or by transfer-
ring genes, which encode therapeutic proteins.  Gene transfers can be carried out us-
ing ex vivo or in vivo methods. In ex vivo approaches, the cells, isolated from the pa-
tient, are modified outside of the patient’s body and then returned to the patient by 
transplantation. In in vivo methods, the therapeutic gene is introduced directly to the 
desired location in the body. Gene therapy is an experimental treatment and that is why 
it can be used only in very serious diseases that lack efficacious treatment; such as 
cancers, cystic fibrosis, duchenne muscular dystrophy and lysosomal storage diseas-
es. Other disease areas which gene therapy is being studied are immunodeficiency 
(ADA, SCID-XI), Parkinson´s disease, Alzheimer´s disease, muscle ischemia, arthritis 
and even AIDS. The gene therapy applications in preventing and treating diseases may 
prove to be more effective and more common in the future than traditional therapy ap-
plications. Furthermore, gene therapy may complete and improve conventional thera-
pies. Successful gene therapy includes clear understanding in pathogenesis of diseas-
es and characteristics of target tissues, effective therapeutic gene or genes, and ap-
propriate animal models for preclinical testing. (Robbins – Ghivizzani 1998: 35-36, 43-
44; Roemer – Friedmann 1992: 211-212; Ylä-Herttuala  2009: 1729, 1733, 1735.) 
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Nucleic acids degrade quickly in the body by the influence of nucleases, and naked 
DNA enters cells poorly. Therefore, gene transfer requires the use of gene carriers, 
also known as vectors. Virus is an organism which is specialized to transport its genes 
to host cells. Because of this character, viruses can be modified into efficient vectors 
for gene transfers. Nevertheless, both viral and nonviral vectors have been generated 
for this purpose. The efficiency of DNA transfer depends on the target-cell type and the 
state of cellular replication at the time of delivery, and even the most developed virus 
vector systems has its limitation.  Hence, it is unrealistic to imagine that only one virus 
vector is suitable for all applications in gene therapy. So, there are virus vectors from 
many different virus families. Viruses have evolved as highly effective tools for gene 
delivery to specific cell types. However, viruses are pathogens and more or less immu-
nogenic. Nonviral vectors are mainly nonpathogenic, but are at the same time less effi-
cient in the gene transfer. Vector systems require further modification and development 
to make the vector more suitable and specific for gene therapy applications. (Hukkanen 
– Hemminki – Ylä-Herttuala 2010: 706-707; Robbins – Ghivizzani 1998: 36, 45; Roe-
mer – Friedmann 1992: 212.)  
 
Depending on the disease, the treatment requires either long-term g or short-term gene 
expression. Inherited diseases require long-term gene expression which is possible 
with virus vectors that integrate their gene into host cell genome, such as retroviruses, 
adeno-associated viruses (AAV) and lentiviruses. The ability of these viruses to insert 
their genome into the cellular DNA allows the expression of a therapeutic gene for the 
life of the infected cell. For the treatment of acquired diseases, like cancer, a therapeu-
tic gene is transferred into the body. For this purpose virus vectors with short-term 
gene expression can be used. (Robbins – Ghivizzani 1998: 36-40; Ylä-Herttuala – 
Äyräpää 2009: 1730-1731, 1733.)  It also possible to develop a chimeric virus system  
in which features of one viral system are combined with features of another viral sys-
tem. This type of approach can make the gene expression more effective. Genes can 
be delivered into cell also with nonviral vectors, such as liposomes, gene gun, DNA 
conjugates, nonviral hybrids and transposons. These nonviral vectors are nonpatho-
genic and relatively cheap and easy to produce, but the efficiency compared to viral 
vector is poorer.  (Robbins – Ghivizzani 1998:41-42; Ylä-Herttuala  2009: 1733.) 
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2.2 Gene Therapy for Cancer 
 
The term gene therapy includes a wide range of treatments that all use genetic material 
to modify cells (Cross – Burmester 2006: 218). In the review article of Deanna Cross 
and James Burmester, the field of cancer gene therapy is broken into three categories: 
gene transfer, immunotherapy and oncolytic virotherapy.  
 
In gene transfer or insertion, the foreign gene (therapeutic gene) is introduced into the 
cancer cell or surrounding tissue. A number of different genes have been proposed as 
therapeutic agents, including suicide genes, antiangiogenesis genes and cellular stasis 
genes. For delivering these genes a number of viral and nonviral vectors have been 
used in clinical trials. Most commonly used and currently most efficient viral vector has 
been replication incompetent adenovirus. The advantages of adenovirus based vectors 
are the ability of infecting dividing and nondividing cells and the ability of achieving a 
high level transient gene expression. Herpes simplex virus (HSV) is also being devel-
oped for gene therapy applications. The ability to cause a latent infection in neuronal 
cells makes HSV an attractive vector especially for treating neurological disorders. The 
choice of delivery vector depends on the specificity and desired duration of the gene 
transfer therapy. With integration capable viruses extra precautions must be taken to 
ensure the therapeutic gene does not integrate into unwanted cell type or to unwanted 
area of the genome. (Cross – Burmester 2006: 223; Robbins – Ghivizzani 1998: 37-
38.) 
 
One goal of cancer treatment has been to harness the immune system and to invoke 
long-term immune response to target and destroy cancer cells without autoimmunity. 
Immunotherapy aims to eradicate the tumor cells by increasing the patient’s immune 
responses against tumor antigens. For this purpose recombinant cancer vaccines has 
been created. Live cancer vaccines are not meant to prevent diseases, but stimulate 
the immune system to recognize the cancer cells. (Cross – Burmester 2006: 219.) The 
development of an effective cancer vaccine requires an efficient antigen delivery sys-
tem. For this purpose various bacterial and viral vectors have attracted a great atten-
tion. The advantage of live vectors is their ability to produce the desired antigen in its 
native form, which is important in production of neutralizing antibodies. Attenuated bac-
teria vectors, like Salmonella, Listeria monocytogenes and Lactococcus latis, have 
many advantages that make them suitable for cancer treatment. They are quite inex-
pensive to prepare, powerful immune stimulators, safe and well tolerated and treatable 
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with antibiotics. (Bolhassani – Zahedifard 2012: 1733-1734.) Viral vectors are capable 
for inducing antibody responses and eliciting T lymphocytes, which are important for 
control of intracellular pathogens and cancer.  Many viruses have been evaluated as 
recombinant vectors for vaccines, such as alphaviruses, adeno-associated viruses, 
poliovirus and hepatitis B virus. The most widely used evaluated vectors are human 
adenovirus and some types of poxviruses. (Bolhassani – Zahedifard 2012: 1738). 
 
Oncolytic viruses hold a great potential as novel therapeutic agents for treating malig-
nancies like cancer.  Oncolytic viruses are genetically engineered to specifically infect 
and destroy cancer cells, while being not harmful for the rest of the body. Oncolytic 
viruses destroy cancer cells by spreading of the virus, expression of cytotoxic proteins 
and lysing the cell through virus replication. Many different viruses have been used as 
oncolytic vectors, including vaccinia virus, adeno virus, herpes simplex virus type 1, 
reovirus and Newcastle disease virus. Many of viruses chosen for this purpose have a 
natural tropism to cancer cells. The results from oncolytic virus therapies have been 
promising. However, the therapy has some challenging obstacles. One of these is the 
existing antibodies in humans which may clear the viral agent before it has time to in-
fect cells. The clinical trials are also more expensive and complicated because of safe-
ty issues in use of replication competent viruses. (Cross – Burmester 2006: 221-222.)  
 
2.3 Vaccinia Virus 
 
Vaccinia Virus (VV) has the longest and most extensive history of use in humans and 
has been studied extensively in the laboratory. VV is the first animal virus seen micro-
scopically, grown in tissue culture, accurately titered, physically purified, and chemically 
analyzed. VV is known for its role in smallpox eradication as an effective smallpox vac-
cine. There are many strains of VV with different characteristics, pathogenicity and host 
range. Western Reserve (WR) is one of the most commonly used strains in laboratory 
and preclinical studies. (Moss 2001:2849-2850; Shen – Nemunatis 2005: 180-181.) 
 
Vaccinia virus is a member of a Poxviridae family and belongs to Orthopoxvirus genus. 
VV has a wide host range and the ability to replicate in almost all vertebrate or inverte-
brate cell types. The replication of the virus occurs in the cytoplasm of the infected cell. 
The origin and the natural host of VV are unknown. The VV virion is a large, physically 
complex, brick- or oval-shaped particle with highly organized subvirion structure (figure 
1).  VV is one of the largest known viruses, with virion dimensions of 300 x 240 x 120 
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nm (Moss 2001: 2849-2851; Shen – Nemunatis 2005:181).The genome composes of a 
single linear double-stranded (ds) DNA molecule of approximate 195 kilobase pairs 
with hairpin loop at each end (Laliberte - Moss 2010: 973; Moss 2001:2850).    
 
VV produces three forms of infectious particles (Shen – Nemunatis 2005: 181). The 
majority of the VV particles are of the mature virion (MV) form (alternate name intracel-
lular mature virion: IMV). MV form is the simplest infectious form of poxvirus particles 
with only a single lipid bilayer envelope.  Mature virions are released upon cell lysis and 
may be important for animal-to-animal transmission. In addition, there is less abundant 
enveloped virion (EV, including cell-associated enveloped virion [CEV] and extracellu-
lar enveloped virion [EEV]), which is essentially an MV with additional lipoprotein mem-
brane. EVs are released from the host cell by exocytosis, without lysing the cell. EVs 
are important for efficient virus spread inside the infected host. The additional lipid 
membrane protects EVs against host immune defenses. The cell-associated EV is 
largely responsible for cell-to-cell spread. MV and EV forms are antigenically different 
from each other. (Laliberte – Moss 2010: 973, 979.)   
 
Figure 1.  Structure of vaccinia virion (Eposito – Fenner 2001: 2886.) 
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Due to the multiple forms of infectious virions, the process of cell entry by VV is not well 
understood and the receptor for infection has not been identified (Shen – Nemunatis 
2004: 181).  MV particles can enter, and release the viral core, to the host cell cytosol 
by both direct fusion with the plasma membrane and fusion with endosomal vesicles. 
These two actions can occur even in the same cell. Entry of EV particle requires rup-
ture of the outer membrane “wrapper” to expose the MV membrane. Thus, EV particles 
shed their extra membrane prior to direct fusion of the MV membrane with the cell 
plasma membrane. Entry through endosomal route is also possible for EV.  It has been 
observed that the EV outer, “wrapper”, membrane is not fusogenic with cell plasma 
membrane. (Laliberte ‒ Moss 2010: 974, 976.) 
 
The entire life cycle of VV occurs in the cytoplasm of host cells. The double-stranded 
DNA genome, packaged in the viral core, encodes approximately 200 gene products. 
These gene products include, for example, RNA polymerase, early transcription fac-
tors, mRNA capping enzymes and protein kinases, which enables viral protein synthe-
sis and virion assembly. (Laliberte – Moss 2010: 973; Shen – Nemunatis 2005:181; 
Wagner – Hewlett 2004: 338.) VV expresses a temporally-regulated gene expression 
program. That is, viral replication can be separated into three specific temporal phases 
in the infected cells. VV replication is initiated by entry of the viral core into the cyto-
plasm where the following steps of the cycle take place. The replication occurs at spe-
cial sites in cytoplasm termed viral factories. During early events the virion is partially 
uncoated to enable the synthesis and expression of early viral proteins required for 
DNA replication. The replication of viral DNA is followed by expression of intermediate 
proteins during the intermediate stages of replication. Late mRNA encodes late gene 
products which consist mainly of structural proteins needed in virion assembly and oth-
er proteins involved with virus maturation. In summary, expression of early genes trig-
gers the expression of intermediate genes which encodes late gene specific transcrip-
tion factors. (Laliberte – Moss 2010: 973; Shen – Nemunatis 2005: 182; Wagner – 
Hewlett 2004: 338-340.)  The entire life cycle of VV takes approximately 24 hours, 
whereupon as many as 10,000 IMV particles are released upon cell lysis. CEV and 
EEV particles may be released from cells as soon as 6 hours after post-infection and 
allow rapid long-term spread. (Shen – Nemunatis 2005:187-188.)  
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2.4 Vaccinia Virus in Gene Therapy 
 
Vaccinia virus (VV) has been studied for its use in cancer gene therapy mainly in three 
ways: as a gene therapy vector of therapeutic genes, as a tumor selective replicating 
oncolytic virus and as a cancer vaccine expressing tumor antigens and/ or 
immunostimulatory molecules. A number of unique features make VV attractive for 
research and in the development of biotherapeutics. VV is highly immunogenic virus 
and is able to elicit both strong T-cell mediated and antibody responses. This character 
makes VV an efficient vaccine. VV can be studied in many different animal models, due 
to its wide host range. The entire replication cycle of VV occurs in the cytoplasm of the 
host cell, so the genome of virus never enters to the cell nucleus. Hence, there is no 
possibility of DNA integration. In addition, in the unlikely case of uncontrolled replica-
tion, there are several antiviral agents available. Furthermore, VV can be produced to 
relatively high titers, the particles are stable and can be stored both in frozen solution 
and dry powder without significant loss of infectivity. (Guse et al. 2011: 596.) 
 
VV can be used as a vector for therapeutic genes. VV has the capacity to hold up to 25 
kb of foreign DNA in its genome, gene expression occurs extremely efficiently and it is 
capable to infect many different tissues. Although VV is highly immunogenic, which 
may lead to rapid clearance of the vector, efficient infection is possible despite the 
presence of neutralizing antibodies. The VV strains most widely used are highly atten-
uated, such as Modified Vaccinia Ankara (MVA) and New York Vaccinia virus 
(NYVAC). (Guse et al. 2011: 596-597.) 
 
As previously mentioned, VV is highly immunogenic and it is capable of inducing strong 
humoral and cell mediated immune responses. In addition, VV infection provides “dan-
ger signals” that help to shape T cell responses effectively. Thus, VV represent an at-
tractive candidate for cancer immunotherapy. A number of VV vector based cancer 
vaccines have shown promising results in several preclinical and clinical trials. For in-
stance, VV has been engineered to deliver tumor-associated antigens (TAAs) to elicit 
antigen-specific immune responses, or immune modulating genes, like cytokines and 
costimulatory molecules, to change the tumor’s microenvironment. (Shen – Nemunatis 
2005: 185.)      
 
VV is also very attractive vector for developing oncolytic viruses, due to its efficient 
replication, cell lysis, spread, broad host range, natural tropism to tumor tissues and 
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remarkable safety record in human use (Shen – Nemunatis 2005:187). The virus has 
been genetically modified to create an oncolytic vector that specifically infect and repli-
cate in tumor cells. Western Reverse (WR) strain has been used for tumor-selective 
oncolytic VV because it is more efficient in killing cancer cells than other strains. (Shen 
– Nemunatis 2005: 188.)  
 
The strategies used to create tumor-selective oncolytic viruses can be grouped in to 
three categories. The first strategy is to delete such gene functions that are crucial for 
efficient viral replication in normal cells but unnecessary in tumor cells. The second 
strategy is to limit the expression of critical viral gene to tumor tissues through the use 
of certain promoters. The third strategy is to modify viral tropism through modification of 
surface proteins. An example of generating tumor specificity of VV using the gene dele-
tion are the deletions of the thyminide kinase (TK) and vaccinia growth factor (VGF) 
genes. TK is necessary for replication in normal cells, but is not necessary in cancer 
cells because of high concentrations of intracellular nucleotides in these cells. VGF 
involves in proliferation in normal cells, but is dispensable in tumor cells because they 
are naturally proliferating. Thus, virus with the VGF gene deleted replicates primarily in 
tumor cells. Double deletion (dd) of TK and VGF enhances the tumor specificity further. 
(Shen – Nemunatis 2005: 188-189.) 
  
3 Final Project Aims 
 
Virus preparation process requires special expertise. To be able to carry out a high-
quality large scale vaccinia virus preparation, the methods and techniques need to be 
properly practiced. The preparation is always carried out by humans and hence the 
qualification of the worker correlates directly with the results, in this case with the virus 
titer. High quality and reliable high titer of virus preparation require competent workers. 
Hence, the main aim of my project was to carry out a large scale vaccinia virus prepa-
ration with assistance of experts, and learn and practice the methods and techniques to 
be able to ensure high quality. In addition, another goal was to describe the different 
stages of the process. 
 
Routine cell culture generally demands the use of fetal bovine serum (FBS) as constit-
uent of complete growth medium to ensure proper cell growth. Nevertheless, serious 
ethical concerns are raised about the harvest and collection of FBS, focused mainly on 
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the painful methods of collecting the serum from animals. In addition to ethical con-
cerns, serum has a number of other disadvantages, such as physiological variability, 
qualitative variation in the composition, cost, and it may contain adverse factors or it 
can be a potential source of microbial contaminants, like bacteria, viruses and prions. 
Hence, the use of animal proteins in cell cultures needs to be decreased for ethical and 
practical reasons as well as for involved safety issues. (Freshney 2005: 129, 132-134; 
Gstraunthaler 2003: 275-276.) Due to these facts, one aim of my work was to investi-
gate how serum-free culture affects to cell viability of A549 cells and virus production.     
 
Virus titers have inherently large deviation, due to biological variation and variations in 
serial limiting dilutions. These sources of error are only partly controlled. In addition, the 
practical problems in titer assays are that they are time consuming and require cell 
culture reagents and skilled personnel. Accurate titer determination is vital for the relia-
bility of any preclinical experiment and clinical studies. (David – LaBarre – Lowy 2001: 
107-108.) Therefore, it is important, that the defined virus titers are reliable. Hence, one 
objective of my project was to compare the common plaque titering assay with TCID50 
assay, and to compare the result with each other.  
 
The purpose of my final project is summarized in the specific aims below:  
 
• To learn how to make a large scale preparation of VV with high quality and high 
virus yield and describe the preparation process. 
 
• To evaluate the effect of serum-free medium on A549 cell cultures. 
 
• To evaluate whether vaccinia virus can be produced without using the serum in 
viral culture medium. 
 
• To evaluate whether TCID50 assay can be used as reliable titering method in 
VV preparations. 
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4 Materials and Methods in Vaccinia Virus Preparation Process 
 
4.1 Cell lines 
 
When choosing the cell line, specific functional requirements and a number of general 
parameters need to be considered. It is essential to consider whether the cell line 
needs to be finite or continuous, normal or transformed, and the importance of the spe-
cies. One important issue is the growth characteristics of the cells, such as doubling 
time, yield, plating efficiency, growth fraction and the ability to grow in suspension. 
Some other considerations are in addition availability of the cell line, how well the cell 
line is characterized, expression of phenotype, is a control cell line required and how 
stable is the cell line. (Freshney 2005: 204-205.) In this process there were two cell 
lines in use in CGTG, Vero and A549 cell line. 
 
In this project, the A549 cell line was used for viral culture and to test the effect of se-
rum-free growth medium on cell viability. A549 cell line was obtained from American 
Type Culture Collection (ATCC), The Global Bioresource Center.  The A549 cells are 
from lung carcinomatous tissue from a 58-year-old Caucasian male. The cell line was 
initiated in 1972 by D.J. Giard, et al. through explant culture. The cells are hypotriploid 
with modal chromosome number of 66. The chromosomes are abnormal with unusual 
amount of chromosome copies in cells and other chromosome mutations. Biosafety 
level with this cell line is 1, so appropriate safety procedures are always needed. Cell 
line is intended only for research purposes. (Product Information Sheet for ATCC CCL-
185™: 1-2.) The detailed instructions for handling and subculturing are found from 
product information sheet.  
 
In this project, the Vero cell line was used in both virus titration methods. Vero cells 
were a kind gift of John Bell, Ottawa Health Research Institute, Canada. This Vero cell 
line has been in use in GGTG for many years. Vero cells are from the kidney of a nor-
mal adult African green monkey. The cell line was initiated in1962, by Y. Yasumura and 
Y. Kawakita in Chiba, Japan. Vero cell line has hypodiploid chromosome count, with 
modal chromosome number of 58. Biosafety level is 1, so appropriate safety proce-
dures are always needed with this cell line as well. Also this cell line is intended only for 
research purposes. (Product Information Sheet for ATCC CCL-81™: 1-2.) Elaborated 
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instructions for handling and subculturing are found in the specific product information 
sheet. 
 
4.2 Recombinant Vaccinia Virus vvD-GFP 
 
This recombinant vaccinia virus was kindly provided by Andrea McCart, Toronto Gen-
eral Research Institute, Canada.  This virus has also been used in CGTG’s previous 
studies. The strain of this recombinant vaccinia virus is Western Reserve (WR). This 
vvD-GFP has a deletion in its thyminide kinase (TK) gene and a green fluorescent pro-
tein (GFP) gene as transgene in its genome. Specifically, the TK gene has been deac-
tivated by adding a sequence of foreign DNA, the GFP gene, in the middle of the func-
tional TK gene. The virus can be used as oncolytic virus vector.      
 
4.3 Aseptic Technique 
 
Tissue culture can be contaminated easily by microorganisms, such as bacteria, myco-
plasma, yeast and fungal spores. Contamination can be confined only to one or two 
cultures, or it can spread and infect the whole experiment. In the worst case, the con-
tamination can ruin even the laboratory’s whole stock. The source of contamination can 
be the operator itself, the atmosphere, work surfaces, solutions or some other factor. 
With proper aseptic technique it is possible to minimize the risk and even eliminate 
such contaminants. A strict code of practice and commitment to it is essential. 
(Freshney 2005: 73.) 
 
To minimize the risk of contamination the cultures need to be checked by eye and on a 
microscope every time they are handled, reagents and bottles of medium need to be 
checked for sterility and not shared with other people or used for different cell lines and 
the standard of sterile technique is always kept high. Aseptic technique provides a bar-
rier between non sterile environment and uncontaminated culture within its flask or oth-
er dish. Hence, all material and equipment which will have a direct contact with culture 
need to be absolutely sterile. (Freshney 2005: 73.)  
 
Aseptic environment has some certain elements. The area or room for sterile work 
should be selected so that it is free from air currents, like doors and windows, and have 
no through traffic. A use of laminar flow cabinet, the hood, is highly recommended. The 
13 
 
area should be kept clean and free from dust, and contain only equipment used in tis-
sue culture. Activity in the area should be limited to tissue culture and all nonsterile 
activities should carry out elsewhere. Keeping the work surface clean and tidy is cru-
cial. The work should always start and finish with a completely clean work surface. 
Generally, the surfaces are wiped before and during the work with 70% alcohol. Per-
sonal hygiene of the operator is also essential, including proper hand hygiene, use of 
gloves or other protective device when needed, long hair tied back and keeping talking 
to a minimum. Medium and reagents should be wiped with 70% alcohol always when 
they come from refrigerator or water bath, and kept open only in laminar flow cabinet. 
Cultures with different cell line, or virus infected cells, should be handled separately.  
(Freshney 2005: 74-76.) 
 
Sterile handling includes wiping with 70% alcohol, use of clean caps, most preferably 
deep screw caps, and occasionally even flaming. In addition, 1.5% Barrydin and UV 
light can be used in culture rooms to destroy viruses more effectively. When handling 
bottles and culture flasks, a hand should never pass over an open vessel. Therefore, 
the bottles and flasks should left open only as short time as needed. The pipettes 
should be disposable plastic pipettes or in some cases standard glass. The pipettes 
packed individually should not be opened until in the hood, and unused pipettes should 
be stored in dust-free container. (Freshney 2005: 76-78.) 
 
The working environment can be protected from dust and other possible contamina-
tions by a constant, stable flow of filtered air passing over the work surface. That is the 
major advantage of working in a laminar flow hood. There are two main types of flow: 
horizontal and vertical flow. In horizontal flow the airflow blows from the side facing 
you, parallel to the working surface and is not recirculated. In vertical flow the air blows 
down from the top of the hood onto the work surface and it is drawn through it and then 
recirculated or vented. Horizontal flow hood gives the best sterile protection to the cul-
ture while vertical flow hood gives more protection to the operator. (Freshney 2005: 78-
79.) 
 
4.4 Culture of Mammalian Cells 
 
Tissue culture was invented already at the beginning of the twentieth century as a 
method for studying the behavior of animal cells. The technique started from growing of 
solid fragments of tissue and developed into disaggregation of explanted cells and into 
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re-plating of these dispersed cells. HeLa cell line was the first continuous human cell 
line established. Tissue culture is used for many applications, such as investigation of 
intracellular activity (DNA transcription, protein synthesis etc.) and intracellular flux, 
investigation of environmental interactions (infection, cytotoxity etc.), cell-to-cell interac-
tions, and investigation of genetics and cell products and secretion. Cancer research 
and virology are highly dependent on tissue culture techniques. (Freshney 2005: 1, 4.)    
 
Cell culture is one type of tissue culture in vitro. Cell culture implies that the tissue from 
the original tissue (primary culture or cell line)  is dispersed mechanically, enzymatically  
or chemically into a cell suspension and is then cultured as an adherent monolayer on 
a solid artificial substrate or free floating in suspension (Freshney 2005: 3, 8.) For suc-
cessful growth and maintenance of mammalian cells in vitro, appropriate culture condi-
tions are required. That means that, growth environment should provide favorable 
growth conditions to the cells, including physiological, physiochemical and nutrient 
conditions. (Gstraunthaler 2003: 276.) 
 
Physiological conditions are defined as the use of appropriate culture dishes which 
allow the cells to attach and spread. Most normal cells grow as adherent monolayer; 
unless they have transformed and become anchorage independent. The cells need to 
attach and spread out on the substrate before they will start to proliferate. (Freshney 
2005: 31.) The substrate must allow adhesion of attachment factors, which will allow 
the cell adhesion and spreading. The extracellular matrix adheres to the substrate, and 
the cells bind to the matrix via specific receptors. For cell adhesion and spreading the 
substrate needs to have slightly negative charge. Glass was the original substrate be-
cause of its optical properties and surface charge, but it has been replaced by irradia-
tion, chemically or electric ion treated plastic, commonly polystyrene. (Freshney 2005: 
31, 105.)  
 
Physiochemical conditions comprise of incubation temperature, constitution of gas 
phase (oxygen requirement), suitable pH (CO2) and osmolality (water status).  The 
temperature recommended for most human and warm-blooded animal cell lines is 
normal body heat, +37°C. For energy production cultured cells are often relying on gly-
colysis which may be anaerobic. Providing the correct oxygen tension is always a 
compromise between fulfilling the respiratory requirement and avoiding toxicity. Dis-
solved oxygen can be toxic to the cells due to the increase of the free radicals. Most 
cell lines grow well at pH 7.4, but the pH varies among different cell strains. CO2 acts 
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as a pH buffer and stabilize the pH in cell cultures. The buffer can be incorporated into 
the growth medium, but exogenous CO2 is generally still required.  The optimum osmo-
lality has been assumed to be at the same level where it would be in origin’s plasma. 
(Freshney 2005: 115-118.) For controlling the humid, temperature and CO2 tension in 
culture atmosphere, a humid CO2 incubator is optimal. It will circulate the air around 
and keeps the temperature and CO2 level consistent. (Freshney 2005: 63.) 
 
The culture medium is one of the most important single factors in cell culture. The 
growth medium should contain all essential nutrients for cell metabolism, growth and 
proliferation, such as amino acids, vitamins, salts, glucose, hormones and grow facto-
ries. (Freshney 2005: 115-123; Gstraunthaler 2003: 276.) Serum is generally added to 
culture medium as a supplement. The role of serum in culture medium is to provide 
hormonal factors for cell growth and proliferation; transport proteins carrying hormones, 
minerals, trace elements and lipids; attachment and spreading factors and stabilizing 
and detoxifying factors. (Gstraunthaler 2003: 276-277.) Complete medium signifies a 
medium that has all of needed ingredients added and is ready to use. Some constitu-
ents may be added just before use, such as serum and glutamine. Dulbecco’s modifi-
cation of Eagle’s MEM (DMEM) is a complex medium with high nutrient concentration, 
and is optimized for viral propagation. (Freshney 2005:120.) 
 
The cell lines used in this project were grown in T-175 tissue culture flasks (Tissu Cul-
ture Flask, 550 ml, 175 cm2, with filter, Greiner bio-one) and maintained in a humified 
incubator at 37°C with 5% CO2. Both cell lines were propagated every 3-4 days and 
split 1:2 or 1:3. First, the old medium was aspirated from the T-175 flasks and the cells 
were washed with 5-6 ml of PBS (Phosphate Buffered Saline: 0,0067 M PO4, without 
Ca and Mg, Lonza BioWhittaker). Then, the PBS was aspirated from the flasks and 5 
ml of 1x trypsin (with Versene [EDTA], Lonza BioWhittaker) was added to each flask. 
Flasks were kept in the incubator for 5-10 minutes until the cells were detached. 5ml of 
appropriate medium was added to the flasks to inactivate the trypsin. Finally, the cells 
were suspended by pipetting, added to new flasks with fresh medium containing a total 
volume of 25 ml, and transferred to incubator.  
 
A549 cell line was used for viral culture and to test cytotoxic effects of serum-free 
growth medium. A549 cells were grown in DMEM (Dulbecco´s Modified Eagle´s Medi-
um) with 1 g/l glucose, without L-glutamine (Lonza BioWhittaker). To make complete 
growth medium 1% L-glutamine (200 mM in 0,85% NaCl Solution, Lonza 
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BioWhittaker), 1%  PEN-STREP (10,000 U Penicillin/ml and 10,000 U Streptomycin/ml, 
Lonza BioWhittaker) and 10% FBS (Lonza BioWhittaker) were added.  
 
Vero cell line was used for virus titration with plaque assay and TCID50 assay. Vero 
cells were grown in DMEM (Dulbecco´s Modified Eagle´s Medium) with high 4.5 g/l 
glucose, without L-glutamine (Lonza BioWhittaker). To make complete growth medium 
1% L-glutamine (200 mM in 0,85% NaCl Solution, Lonza BioWhittaker), 1%  PEN-
STREP (10,000 U Penicillin/ml and 10,000 U Streptomycin/ml, Lonza BioWhittaker) 
and 10% FBS (Lonza BioWhittaker) were added.  
 
4.5 Infection with Vaccinia Virus 
 
As previously mentioned, the replication of VV occurs in the cytoplasm of the host cell. 
Therefore, the cells need to be infected by the virus for the virus replication and ampli-
fication to take place. 
 
For large scale VV preparation, ten 100% confluent T-175 flasks of A549 cell were pre-
pared. Because two virus preparations were made, the amount of flasks was double. 
The growth medium was aspirated from the flasks and the cells were infected with vvD-
GFP with a multiplicity of infection (MOI) of 0.1 PFU/cell. The virus stock was main-
tained in Tris base solution (1 mM Tris, pH 9.0) at -80°C until use. For the first VV 
preparation the calculated volume of virus was added to 5 ml of growth medium with 
2% FBS per flask. The other VV preparation was carried out the same way but without 
use of FBS.  5 ml of infecting solution was added to each flask and incubated one hour 
in the incubator at 37°C with 5% CO2. After infection, 25 ml of proper growth medium, 
with 2% FBS or serum-free, was added into the flasks and the flasks were placed in 
incubator at 37°C with 5% CO2  for three days until extensive CPE (cytopathic effect) 
was visible. The cells were monitored daily with microscope for morphological changes 
(CPE). 
 
4.6 Vaccinia Virus Purification 
 
Virus purification means the physical separation of virus from the host cell in which it 
has replicated. Ultracentrifugation is the standard technique for the purification of small 
particles of defined size, like virions, from the contaminating material. Ultracentrifuge is 
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a powerful centrifuge whith maximum speed in excess of 30,000 rpm up to 600,000 g 
with sophisticated refrigeration and vacuum system (Jones – Reed – Weyers  2007: 
362).The particle’s rate of sedimentation depends on the size, density and morphology 
of the particle, but also on the characteristics of the medium in which the particles are 
suspended. With differential centrifugation (pelleting) it is possible to successfully sepa-
rate particles which have large differences between their mass and densities. More 
accurate virus purification can be achieved by the technique of density gradient centrif-
ugation, where separation of the particles is achieved by sedimentation through a den-
sity gradient. Sucrose is an ideal medium for making of sharp and easily isolated bands 
of pure virus (Killington – Stokes – Hierholzer 1996: 71-72, 75.) 
. 
When CPE was visible, the cells with virus in them were collected from the flasks. Cells 
were released by scraping the bottom of the flask with scrapers. The cell suspension, 
loose cells and medium, was collected in 50 ml Falcon tubes. The tubes were spun 
down in a centrifuge with 1000 rpm for 10 minutes at 4°C and the supernatant was then 
discarded. The cell pellets were resuspended altogether with 30 ml of Tris base solu-
tion (1 mM Tris, pH 9.0) and put in freezer at -80°C.    
 
The viruses were released from A549 cells by cell lysing with freeze-thaw cycles. The 
cell suspension was first thawed in water bath, mixed vigorously by using Vortex and 
then frozen at -80°C. Freezing took approximately two hours. This procedure was re-
peated three times. After the last thaw the suspension was spun down in centrifuge 
with 3000 rpm for 10 minutes at 4°C. The supernatant containing the virus was collect-
ed and put on ice. The remaining cell debris pellet was resuspended with 10 ml of Tris 
base solution (1 mM Tris, pH 9.0), mixed by using Vortex and spun down. The super-
natant was also collected from the latter and combined with earlier collected superna-
tant. This was performed to ensure that all virus particles are used in the further purifi-
cation.  
 
The actual purification was performed by differential centrifugation with a sucrose gra-
dient. 10 ml of 36% sucrose was added to two ultracentrifuge tubes (Ultra-Clear™ Cen-
trifuge Tubes, 25 x 89 mm; Beckman). The viral sample (supernatant) was then layered 
carefully on top of the sucrose cushion. Before ultracentrifugation, the tubes were accu-
rately balanced using a scale. Then, the tubes were centrifuged for 90 minutes at 
20,000 g at 4°C using Optima™ XL-80K Ultracentrifuge, Beckman Coulter. During ul-
tracentrifugation the virus pellet travelled through the sucrose cushion to the bottom of 
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the tube. After centrifugation, the supernatant was instantly discarded from the tube, 
carefully without disturbing the pellet. Viral pellets from two tubes were resuspended 
with 1 ml of Tris base solution (1 mM Tris, pH 9.0) and combined. Finally, the virus 
suspension was divided to aliquots in Eppendorf tubes and stored in freezer at -80 °C.  
Eppendorf tubes and tags for storing the virus aliquots were prepared while tubes were 
centrifuged. 
 
4.7 Quantification of Vaccinia Virus and Titer Calculations 
 
The concentration of the infectious virus particles is essential for most virology experi-
ments. Animal viruses are quantified by infectivity assay (e.g. TCID50 and plaque as-
say), by some other biological or chemical assay (e.g. haemagglutination) or by direct 
total virus particle counting using the electron microscope. Plaque assay has been 
considered to be the easiest, most accurate and sensitive form of assaying virus infec-
tivity. However, plaque assay has some disadvantages and hence other methods are 
needed. (Hierholzer – Killington 1996: 35.)  
 
The replication of virus in the host cell causes several biochemical and morphological 
changes within the cell and generally results in cell death. These morphological chang-
es are called as cytopathic effect (CPE) which may take several forms, such as cell 
rounding, cell fusion or total cell lysis. CPE can be visible by naked eye, but it is gener-
ally observed with light microscope. Infectivity assays are designed to enable the calcu-
lation of virus titer (the number of infectious units per unit volume). A virus particle able 
to instigate an infection, in other words an infectious unit, is called a plaque forming unit 
(PFU) (Wagner – Hewlett 2004: 136).  Determination of virus titer by infectivity assays 
requires making accurate serial dilutions of virus suspension. 10-fold dilutions are 
commonly carried out for routine use. (Hierholzer – Killington 1996: 35-36.) 
 
4.7.1 Plaque Assay 
 
The plaque assay quantifies the number of infectious units in a given virus suspension. 
Plaques are discrete foci of infection originated from a single infectious virion. A plaque 
denotes a spot of cell lysis or CPE, in other words a hole, within the cell monolayer. In 
monolayer plaque assay the virus dilution is added to the previously seeded confluent 
cell monolayer for virus infiltration. Before incubation an overlay medium, composed 
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from agarose, is added to the cell monolayer. This overlay medium prevent the devel-
opment of secondary plaques by forcing the released virus particles from the infected 
cell to infect only neighbouring cells. The assay dishes are then incubated at appropri-
ate temperature until the plaques are visible. Finally, the plates are fixed, stained with 
crystal violet and observed either with the naked eye or with microscope. For statistical 
reasons, to minimize the error, 20-100 plaques per monolayer (e.g. well) are ideal to 
count. The infectivity titer is expressed as the number of the plaque forming units per 
ml (PFU/ml). (Hierholzer – Killington 1996: 38.) The formula below can be used for cal-
culation of the titer of a virus stock: 
 
Vf = V0 / D 
 
Vf is the final concentration (PFU/ml), V0 is the original concentration in ml (number of 
viruses i.e. plaques in the volume of diluted virus solution per well) and D is the dilution 
factor. (Wagner – Hewlett 2004: 138.)  In other words, the calculation can be carried 
out as following:  
 
Number of plaques/ (dilution factor x volume of diluted virus solution) 
 
E.g. If the average number of plaques is 50 in the 10-5 dilution well, and if the volume of 
added diluted virus solution is 1 ml, the titer is then 50/ (0.0001 x 1) = 5 x 105 PFU/ml.   
 
In this project the plaque assays were performed according to the instructions in ap-
pendix 3. Virus quantification with plaque assay was carried out with two 6 well plates 
per virus preparation in parallel. Vero cells were seeded at 1 x 106 cells per well in 2 ml 
growth medium with 2% FBS per well. Cells were incubated in the incubator at 37°C 
with 5% CO2 for 24 hours, and infected with five ten-fold virus dilutions (10-5-10-9). 1 ml 
of each of five virus dilution was added to one well on the plate and incubated for one 
hour in the incubator. One well was used as negative control (mock) which received 
growth medium with 2% FBS without any virus. After infection, virus dilutions were as-
pirated from the wells, and the cells were overlaid with 1.3% agarose (Bactoagar) 
mixed with 2xDMEM (1:1). After three days, the occurrence of plaques was checked 
with a microscope. The cells were then fixed with methanol-acetic acid fixative and 
stained with Coomassie® Brilliant Blue staining solution (Bio-Rad). Then, plaques of 
the two plates were counted manually, and the titer was determined as the average of 
PFU/ml titers of the single plate. In figure 2 is an example of a 6-well plaque assay 
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plate. The cell monolayer is stained blue, and the plaques can be seen as clear 
punctures.   
 
 
Figure 2. An example of plaque assay plate, and plaques in different virus dilutions. 
 
4.7.2 TCID50 Assay 
 
TCID50 is an abbreviation for median tissue culture infectious dose, which denotes the 
amount of a virus required to infect 50% of inoculated cell cultures. TCID50 is a dilution 
endpoint method and the assay relies on presence and detection of virus particles ca-
pable to produce CPE.  The virus dilutions are added to host cells which are grown in 
confluent monolayers in 96-well tissue culture plates. The number of wells per dilution 
affects to the accuracy of the method. During the incubation the virus replicates and the 
released progeny virions infect the healthy cells in the monolayer. The CPE is allowed 
to develop over period of days and during that time the monolayers are observed mi-
croscopically. The time required depends on virus and host cell type. After incubation 
the wells are scored for the presence of CPE and the TCID50 is calculated either by the 
Reed-Muench or by the Spearman-Kärber method. The results do not directly indicate 
how many infectious units are present, but reflect the dilution of virus which produces 
CPE in 50% of the inoculated cells. TCID50 relates to the average number of PFUs in 
the aliquot, and thus it is possible to transform the results in PFU/ml. (Hierholzer – 
Killington 1996: 36; Wagner – Hewlett 2004: 141-142.)        
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In this project, two 96-well plates were prepared for parallel quantification of each virus 
preparation.  TCID50 was performed by seeding the Vero cells at 1 x 104 cells per well 
in 96 well plate with 100 µl growth medium with 2% FBS per well.  After incubation for 
24 hours in the incubator, the cells were infected with 100 µl per well of virus sample 
from both virus preparations. Each 96 well plate was infected with eight ten-fold virus 
dilution series (10-5-10-12), so that each plate had all eight dilutions and two negative 
control columns. TCID50 was carried out according the instructions in appendix 4.  After 
10 days, the plates were read manually with a microscope to determine CPE of each 
well, and the titers were calculated using the Spearman-Kärber statistical method and 
then transformed in PFU/ml. The formula below was used to calculate the titers: 
 
T= 101+d(S-0.5) 
 
T is the titer for 100 µl aliquot of virus, d is the log 10 of the dilution (1 for ten-fold dilu-
tion) and S is the sum of ratios. After this calculation, the titers in TCID50/µl were trans-
formed into TCID50/ml and futher to PFU/ml. First, the titer in TCID50/µl was multiply by 
10 to get the titer in TCID50/ml (e.g. 108 TCID50/µl x 10 = 109 TCID50/ml). Then, the titer 
in TCID50/ml was transformed in PFU/ml by subtracting 0.7 from the log of the titer (e.g. 
109-0.7 = 108.3 PFU/ml). (AdEasy™ - Vector System: 39.)  
 
4.8 Detection of GFP transgene with Fluorescent Microscope 
 
Fluorophores (also known as fluorochromes) are certain chemical compounds that ab-
sorb ultraviolet radiation and release some of the radiation energy in the longer, visible 
wavelengths. This phenomenon is called fluorescence. The presence of fluorophores in 
cells can be observed using a fluorescence microscope.  In a fluorescence microscope 
the light source produces a beam of ultraviolet light that travels through a filter. The 
filter blocks all the other wavelengths except that which is capable to excite the 
fluorophore. When the fluorophore has become excited by the beam it starts to emit 
light of visible wavelength. The objects with fluorophore can be seen brightly against a 
black background. (Karp 2005: 737.) 
 
Jellyfish Aequorea victoria produces bioluminescent green light. The light produces 
when calcium binds to its photoprotein called aequorin. Aequorin itself produces blue 
light when activated. However, the jellyfish produces green light. This green light is 
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caused by another protein in A. victoria, the green fluorescent protein (GFP). (Chalfie 
et al. 1994: 802.) Green fluorescent proteins are found in many organisms. However, 
the gene of A. victoria´s GFP was the first which was cloned and expressed. This GFP 
is also used in most of the tracer studies. (Zimmer 2001: 759.) GFP is a protein of 238 
amino acids. The crystal structure of wild-type GFP is dimer and it resembles a shape 
of a cylinder. A cromophore, the “pigment” of GFP fluorophore molecule, is situated in 
the center of the cylinder, and in this way it is well protected in the “can”.  GFP absorbs 
blue light (398 nm - 475 nm) and emits green light (509 nm - 540 nm).  (Chalfie et 
al.1994: 802; Zimmer 2001: 760-761.) Nowadays, the GFP is commonly used as a 
biological marker in molecular biology, medicine and cell biology. GFP has many good 
qualities which make it good research tool in living systems. (Zimmer 2001: 759.)  
 
The ability of vvD-GFP to express GFP protein in infected cells was checked with the 
fluorescence microscope (Zeizz Axiovert 200; Carl Zeizz Inc.)  Vero cells from one 
plaque assay plate were examined and photographs were taken.  
 
4.9 Effects of Serum-free Medium on A549 Cell Growth in vitro 
 
According to the ATCC product information sheet for A549 cell line, the complete 
growth medium needs to contain 10% of FBS. Hence, the interest was to investigate 
how serum-free medium affects to the cell viability of A549 cells compared to the com-
plete medium. A549 cells were incubated 1-3 days in both serum-free growth medium 
and in complete growth medium with 10% FBS. Cell viability was measured using 
tetrazolium (MTS) based colorimetric CellTiter 96® AQueous One Solution Cell Prolifera-
tion assay on day one, two and three.  
 
4.9.1 Execution of Cell Viability Measurement for A549 Cells 
 
A549 cells were seeded in 16 wells (two columns) in three 96-well plates. A549 cells 
were seeded at 1 x 104 cells per well in 100 µl growth medium with 10% FBS and incu-
bated for 24 hours.  On next day the medium was changed. Old medium was aspirated 
carefully from each well, then 100 µl of medium with 10% FBS was added to wells in 
first column and 100 µl of serum-free medium was added to the wells in second column 
(Figure 3).  The procedure was repeated to ensure absence of serum in wells with se-
rum-free medium. The cell viability of A549 cells in different serum concentrations was 
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measured using CellTiter 96® AQueous One Solution Cell Proliferation Assay. The 
measurement was carried out for one, two and three days after the medium change.  In 
addition, the cells were checked daily with light microscope. 
 
A 10% 0% 
          
B 10% 0% 
          
C 10% 0% 
          
D 10% 0% 
          
E 10% 0% 
          
F 10% 0% 
          
G 10% 0% 
          
H 10% 0% 
          
Figure 3. Example of media with different serum concentrations on 96-well plate in cell        
 viability assay. 
 
4.9.2 Measuring the Cell Viability with CellTiter 96® AQueous One Solution Cell Prolif-
eration Assay 
 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) is a colorimetric 
method for determining the number of viable cells in proliferation or cytotoxity assays. 
The reagent contains a novel tetrazolium compound (MTS) and electron coupling rea-
gent (PES). Metabolically active cells bioreduce the MTS tetrazolium compound into a 
colored formazan product that is soluble in tissue culture medium. The assay is per-
formed by adding 20 µl of the reagent directly to culture wells and incubating 1 – 4 
hours. After incubation the absorbance is recorded at 490 nm with 96-well reader. The 
amount of 490 nm absorbance is directly proportional to the number of living cells in 
culture. (CellTiter 96® AQueous One Solution Cell Proliferation Assay. Technical bulletin 
No. 245.) 
 
Before adding the reagent, fresh medium with 10% FBS was changed to each culture 
well. Medium had to be the same in all wells because of the color. In addition, four 
wells with no cells (blank) were filled with the same medium as background control. 
After medium change, 20 µl of CellTiter 96® AQueous One Solution- reagent was added 
to each well and incubated one hour. After incubation, the absorbance from the wells 
was recorded at 490 nm with spectrophotometric plate reader (Multiskan Ascent, 
Thermo Labsystems) and results were analyzed with MS Excel. 
 5 Results 
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Figure 4. Work flow diagram of vaccinia virus preparation process.
 
The presence of GFP transgene in 
cence microscopy. Vero cell monolayers infected with virus of the vvD
developed plaque (Figure 5 D)
tion, PCR for the viruses’ TK region 
Preparation of 10 
confluent T-175 
flasks of A549 
cells
Virus purification 
by 
ultracentrifugation
Aliquoting and 
storage at -80°C
 Vaccinia Virus Using Standard Techniques
can be found on appendices 1 
preparation according to the plaque assay results 
 the titer of previous vvD-GFP
5.5 x 108 PFU/ml). The stag
 process are shown in the workflow diagram below (F
 
vaccinia virus genome was indicated with fluore
, which was positive for GFP (Figure 5
was carried out. The PCR was carried out with two 
Infection with 
vaccinia virus (amplification of 
Collection of the 
from the flasks by 
3 freeze-thaw 
cycles to release 
the viruses from 
the cells
Quantification of 
the virus titer
24 
 
, according to the 
was 7.6 
 preparation, which 
es of the large 
igure 4).  
 
s-
-GFP preparation 
 E and F). In addi-
Incubation until 
visible CPE 
the virus)
infected cells 
scraping
25 
 
primer combinations, namely TK_F (forward) and P7.5 R (reverse) and P7.5 F (for-
ward) and TK_R (reverse). The PCR was partly successful, having a positive band with 
primer combination of P7.5 F and TK_R and negative water controls (Figure 6). How-
ever, due to the absence of positive control the PCR results cannot be considered 
completely reliable. 
 
 
Figure 5. Fluorescence microscope picture of viral GFP in Vero cell culture. Normal Vero cells 
 in negative control well (A), a brightfield picture of negative control (B), a GFP picture 
 of negative control (C). A plaque in Vero cell monolayer developed by vvD-GFP pre-
 paration (D), a brightfield picture of GFP positive plaque (E), a GFP picture of GFP 
 positive plaque (F).    
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Figure 6. A positive band in gel electrophoresis with primer combination of P7.5 F and TK_R 
 after amplification of viral DNA via PCR. Water controls are negative. Positive control 
 is lacking. 
 
5.2 Effect of Serum-free Growth Medium on A549 Cell Cultures  
 
The effect of serum-free growth medium on A549 cell growth and viability was exam-
ined with MTS assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay). The 
cell growth and viability were monitored for three days and the cell viability assays were 
carried out on three consecutive days; one, two and three days after the medium was 
changed.  The background was taken away from the absorbance and the average of 
absorbance was determined from ten wells (n=10). The results from the assays are 
shown in figure 7. 
 
After incubating for one day the number of live cells in serum-free medium was 76%  
compared to the number of cells in medium with 10% FBS. On second day the number 
of live cell in serum-free medium was 71% and on third day it was 67% compared to 
cultures with 10% FBS. It can only be noted that during the incubation the cells man-
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aged better in medium with serum than in serum-free medium. The standard deviation 
(SD) of absorbance was more uniform in cultures with medium containing serum. The 
standard deviation of absorbance in cultures with serum-free medium varied between 
0.07-0.21, where in cultures with serum it varied between 0.10-0.18. 
 
 
Figure 7. Diagram of ratios of live cells in cultures with 0% and 10% serum (FBS). 
 
5.3 Effect of Serum-free Growth Medium on Vaccinia Virus Yield 
 
 The serum-free growth medium had an influence on the cell growth of A549 cells. 
According to the results, the cell growht was approximately 29% lower in serum-free 
growth medium than in medium with serum. Question remained whether the reduced 
cell growth would affect virus yield to the same extent. 
 
The plaque assay is routinely used in vaccinia virus titration around the world and that 
is why the results from the plaque assay are used for the comparison of the virus titers. 
Figure 8 shows the difference between the titers in serum-free medium and medium 
with 2% serum. The virus titer in normal preparation was 7,6 x 108 PFU/ml and in 
proportion in serum-free medium the virus titer was 6,7 x 108 PFU/ml. Consequently, 
the virus titer in serum-free medium was approximately 12% lower than the virus titer in 
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normal circumstances. This result does not correlate well with the reduced cell growth. 
Alternatively, in TCID50 assay the difference between the titers was bigger (27%) which 
correlates better with the difference  in cell growth (29%). 
 
 
Figure 8. Comparison in virus yields between different serum concentrations by using both titer-
 ing methods. 
 
5.4 Comparison of Titering Methods for Vaccinia Virus Preparation 
 
In this final project, one goal was to evaluate the comparability of two different titering 
methods. In addition to the plaque assay results, the virus titers were quantified also by 
TCID50 assay. The difference in virus titers between these titering methods is shown in 
figure 9.  The titer generated by plaque assay was an average of two plaque assay 
plates (n=2), while the titer generated by TCID50 assay was an average of four 96-well 
plates (n=4). The virus titers generated by TCID50 assay were higher than the titers of 
the plaque assay. The virus titer from normal virus preparation by plaque assay was 
7.60 x 108 PFU/ml (CV 8.4%), where the titer generated by TCID50 was 1.89 x 109 
PFU/ml (CV 10.9%). In serum-free virus preparation the virus titer by plaque assay was 
6.73 x 108 PFU/ml (CV 4.7%) and by TCID50 it was 1.38 x 109 PFU/ml (CV 30.9%). 
Variation in titers was higher in TCID50 assay. The difference between the virus titers 
from virus preparations cultured in different serum concentrations was clearer in TCID50 
than in plaque assay.  
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Figure 9. Comparison of virus titers in different serum concentrations and titering methods. 
 
It was found in the studies that plaque assays yield approximately 55% smaller titers 
than TCID50 assays (Figure 10).      
 
 
Figure 10. Comparison of virus titers between plaque and TCID50 assay. 
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5.5 Reliability of Results 
 
Notable is that this large scale vaccinia virus preparation was the operator’s first one 
which affected the working speed and may have a slight effect on the virus titer. Never-
theless, the virus preparation process was successful. High quality virus preparation 
requires experience. The virus was positive for GFP which was indicated reliably with 
fluorescence microscope. The virus preparation process and all assays were carried 
out according to instructions and with high accuracy. In addition, both tittering assays 
were carried out twice in parallel to ensure the validity of the virus titers. Therefore, the 
results can be considered reliable. However, the first plaque assay plates were impos-
sible to read, so data from plaque assays was smaller. Because of the limited material, 
the results are only suggestive. More data and material are needed for reliable statisti-
cal analysis, for evaluating the significance of the results and for reliable conclusions. 
6 Discussion 
 
6.1 Ethical Speculation 
 
 Medicine has developed from people´s urge to understand the mechanisms of diseas-
es and to be able to avoid and cure them (Karttunen – Soini – Vuopala 2005: 12). An 
international group of Hastings Centers project has defined four goals of medicine: 
“The prevention of disease and injury and the promotion and maintenance of health; 
The relief of pain and suffering caused by maladies; The care and cure of those with a 
malady, and the care on those who cannot be cured; The avoidance of premature 
death and the pursuit of a peaceful death” (The Goals of Medicine: Setting New Priori-
ties 1996: 9-14). Some diseases, like malignant cancers, cannot usually be cured by 
conventional therapies. Therefore, novel therapies are sorely needed. To be able to 
response to these goals of medicine, it is essential to discover and constantly develop 
novel and more efficient treatments and approaches to care and cure patients. (Rajecki 
et al. 2008: 3085, 3091.)   
 
Research work, especially cancer research, requires use of animal models. Animal 
testing is sensitive issue which divides views universally and strikes a chord with a lot 
of people. The issue is nevertheless two-sided; novel therapies are desperately need-
ed, but animal models are often difficult to replace. Recently, a concept of 3R (re-
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placement, reduction, refinement) has fortunately become well-known. These three Rs 
refer to the basics of a humane laboratory animal research: replacement of animal 
models and reduction of number and pain of test animals.  Possibly, by changing the 
culture in science, it is possible to increase the use of alternative methods.  (Hirsijärvi – 
Mäkiniemi – Saunaoja – Siitonen 2005: 103, 106, 113-114.)  
 
The use of test animals for experimental purposes is defined in the Finnish act on the 
use of animals for experimental purposes (Laki koe-eläintoiminnasta 62/2006). The use 
of animals for experimental purposes is allowed only with the permission of the State 
Provincial Office (experimental animal establishment authorization). Animal experi-
ments are authorized in Finland by the national Animal Experiment Board. The objec-
tive of the Act is to ensure that the animals are used and kept for experimental purpos-
es only for necessary and important reasons. The object is also to ensure that a mini-
mum number of animals are used and that the use of animals causes the least possible 
amount of pain, suffering, distress or lasting harm to the animals.  The requirements of 
experimental animal establishments and requirements for the personnel performing the 
experiments are also specified in the act. These statutes may still not be sufficient 
enough to ensure that alternative methods are always used when possible (Hirsijärvi et 
al. 2005: 112). 
 
Serum is commonly used in cell culture medium as one constituent. In most cases, 
routine cell culture demands the use of animal-derived products, mainly fetal bovine 
serum (FBS). The estimated amount of FBS produced for the world market is approxi-
mately 500,000 liter per year, which makes at least 1 million bovine fetuses to be har-
vested. This number is expected to increase annually. The use and the current meth-
ods of collecting FBS raise ethical and moral concerns. In addition, scientific and tech-
nical problems are related to use of FBS in cell cultures. (Gstraunthaler 2003: 275; 
Jochems – van der Valk – Stafleu - Baumans 2002: 219.) The fetal blood is commonly 
harvested by cardiac puncture from at least 3 months old cow fetuses during the 
slaughter of the mother cow. The cardiac puncture is performed without anesthesia and 
hence the fetuses may possibly suffer. (Jochems et al. 2002: 222-223.)  In addition to 
these ethical reasons, the use of animal serum in cell cultures has a number of disad-
vantages; serum is an ill-defined medium supplement, there exist quantitative and qual-
itative variation and it can contain adverse factors and microbial contaminants 
(Gstraunthaler 2003: 277). Especially, when virus is produced for use in humans, the 
major concerns are the contaminants. Special standard in the production of FBS, called 
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Good Manufacturing Practice (GMP), needs then to be fulfilled, which increases the 
price significantly. In addition, prions can not to be tested for and therefore the FBS 
must come from prion-free countries. (Guse 2012.) For all of these reasons above, 
FBS should be replaced or reduce the use of it in cell culture. 
 
Issues around the use of test animals are complicated and there is not one right ap-
proach. Everybody has to decide for themselves what their priority is. Values, morals 
and opinions have influence over the decision of an individual. In my opinion, it is im-
portant to develop alternative methods for animal models and use laboratory animals 
only for medical purposes and only when it is essential for people’s health. However, 
the use of animals for medical and scientific purposes cannot probably ever be com-
pletely replaced. 
 
The history of gene therapy treatment is relatively short compared with other modes of 
treatment. However, during the past few years various studies have been published 
about the efficiency of gene therapy in practice. Some of the results have been posi-
tive. (Rajecki et al. 2008: 3085). Experimental treatments, like gene therapy, may be 
suitable for patients with terminal cancer which has spread in spite of traditional treat-
ments. The patient needs to be in good condition and understand the possible risks 
related to gene therapy. Giving the virus treatment to patients in bad conditions is gen-
erally avoided, because in those cases the treatment can be more harmful than helpful 
to the patient. (Rajecki et al. 2008: 3089-3090.) Some adverse events are related to the 
virus treatments; such as transient fever, malaise, tiredness, skin reactions and pain at 
the injection site. (Guse et. al. 2011: 603; Rajecki et al. 2008: 3090). 
 
To be able to increase the safety of therapeutic viral agent, the replication of the virus 
needs to be tumor-selective. That can be achieved with many mechanistic approaches, 
including the use of viruses with inherent tumor selectivity, gene deletions, engineering 
tumor specific promoters into viruses and modification of the viral coat. Virotherapy 
agents raise unique biosafety and risk management issues. The risks must be as-
sessed not only from the perspective of the treated patient but also from the perspec-
tive of the patient’s contacts and the general public. Good Laboratory Practice and all 
precautions are needed when working with viral agents. Virotherapy agents may be 
less toxic than standard therapeutics, but there will always be a risk of toxicity during 
clinical testing. (Vile – Ando – Kirn 2002: 1063-1064.) 
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In gene therapy only somatic cells may be handled. Hence, the treatment does not 
have an influence to the genotype of the progeny. However, gene therapy can cause 
unintentional side effects. (Räikkä – Rossi 2002: 63.) The introduction of new treat-
ments is normally based on large randomized studies. Although the safety and the effi-
ciency of some cancer treatments being studied, it is still hard to predict whether the 
patient benefit from it. (Rajecki et al. 2008: 3091.) The objective of the Finnish gene 
technology Act is to promote the safe use and development of gene technology in ac-
cordance with the precautionary principle and in a way that is ethically acceptable. A 
further objective is also to protect human and animal health and the environment when 
carrying out the contained use or deliberate release into the environment of genetically 
modified organisms (Geenitekniikkalaki 377/1995). 
 
Some safety concerns are related to oncolytic vaccinia virus treatments. Vaccinia vi-
ruses have not yet been tested as gene therapy agents in large populations to deter-
mine reliably the occurrence of adverse events. However, vaccinia viruses have gener-
ally shown only mild toxicity in clinical cancer trials. The characters of the adverse 
events depend on the strain of the used. Strains with high oncolytic potential are likely 
to have more serious side effects. One safety concern is also the contagiousness of 
the virus. Several cases are reported where recently vaccinated subjects have trans-
mitted a vaccinia virus infection to others. Most of these have occurred in hospitals and 
in almost all cases the individual has been naive to vaccinia virus. However, this conta-
giousness refers to strains that were/are used in smallpox vaccination purposes. (Guse 
et al. 2011: 603.). To be able to increase the safety of therapeutic viral agent, the repli-
cation of the virus needs to be tumor-selective. Oncolytic viruses are genetically modi-
fied and they do not replicate in normal cells (Rajecki et al. 2008: 3090).  
       
Gene therapy holds great promise for effective therapies for cancer. However, the 
proof of efficacy and safety still need to be provided by randomized clinical trials. (Guse 
et al. 2011: 603.)  It is also important to avoid raising the hopes of patients too high as 
this may result in disappointment. Furthermore, gene therapy needs to be available for 
all patients so that inequality in society is avoided (Räikkä – Rossi 2002: 66).  Most 
importantly, it is essential that the treatments cause more advantages than disad-
vantages to the patients. 
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6.2 Reflection 
 
This final project was a brief subproject which related to one more extensive on-going 
project of CGTG. As a product of this project I was able to carry out two successful 
vvD-GFP preparations without any major problems or surprises. These virus prepara-
tions will play a role in an on-going “Safety and efficacy of vvd-TRAS virus pre-
clinically” -animal experiment. In that experiment, the vvD-GFP viruses from the prepa-
rations of this project will function as a negative control to vvd-TRAS viruses. In this 
way, although this final project was rather brief, it will have a small, but still notable role 
in the research work of CGTG.   
 
Along with this project, I updated the work instructions of VV preparation process and 
made some supplements into them. I compiled the work instructions from biomedical 
laboratory technologist’s view, and built them so that person with only a little experi-
ence is able to follow them. I hope that these instructions are helpful in orientation of a 
new staff member or a student, and can be used as a note by current staff. Because 
this VV preparation process was new to me, I think that I was able to compile practical 
and illustrative work instructions. This work instruction process was extremely instruc-
tive and advantageous, because while learning new techniques and methods, I had to 
explore and understand them more deeply. In addition, this process developed my 
skills in information retrieval and gave me confidence to work more independently. 
 
Some different approaches were tested for studying the cytotoxity of serum-free medi-
um on A549 cell cultures. First, I tried to inoculate the cells to the 96-well culture plates 
both in serum-free medium and in medium with 10% FBS, but soon I noticed that the 
cells in serum-free medium started to suffer and died quickly. It seemed that the cells 
did not attach properly to the bottom of the wells in serum-free medium and therefore it 
was not possible to carry out the cell viability assay. Thus, the approach needed to be 
changed. It was more successful to plate the cells first in medium with 10% FBS and 
then change the medium on the next day and start the three days lasting cell incuba-
tion in different serum concentrations. The cell viability of A549 cells was measured on 
each day by MTS assay.  
 
According to the results from cell viability measurements, it was possible to find out that 
serum-free growth medium was more disadvantageous to the cells than medium with 
10% serum. However, VV preparation was possible to carry out successfully in serum-
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free culture, but the virus titer was lower than in culture with 2% serum. Therefore, it is 
possible to carry out VV preparations in serum-free cell cultures, if slightly lower virus 
titer is acceptable. On the other hand, serum-free cell culture has a number of other 
advantages. To be able to see the truthful influence of serum-free culture to VV titer 
and make reliable conclusions, more serum-free VV preparations need to be carried 
out. In addition, new cell viability measurement should be carried out with medium con-
taining 2% serum, because the infection of VV is normally carried out in such serum 
concentration. In that way, the cell growth and the virus yield could be more in propor-
tion with each other.  
 
Finally, based on the titer results of this project; plaque assays yielded lower virus titers 
than TCID50 assays. Because both tittering assays were made twice, it was noticed that 
at each time both methods gave similar results. However, the level of the virus titer was 
different between these two methods. According to the project’s results, TCID50 assay 
gave more than 50% higher titers than common plaque assay. Hence, only one method 
can be in use in the process at the same time, and the titers must be determined using 
the same method, in order for them to be comparable with each other. However, to be 
able to compare these titering methods reliably and to be able to evaluate the statistical 
significance of the results, more data is needed. The results from this study are only 
suggestive. 
 
This whole final project was very interesting, challenging and educational experience. I 
learned a variety of different techniques and methods and increased my theoretical 
knowledge. I had to tolerate uncertainty, find answers and ask for help, but as a reward 
I had experiences of success. I am very satisfied with my thirst of knowledge, with my 
accuracy in work and with my persistence in this process. I feel that I have received 
good supplies for the future. However, I would have needed more practice in my Eng-
lish language skills, in mathematical statistics and skills in use of MS Excel. I feel lucky 
and privileged that I was able to be a part of the valuable work of Cancer Gene Thera-
py Group and meet the people working there. I believe that I will become a qualified 
and enthusiastic biomedical laboratory technologist.  
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